June 7, 2019
Implantable CGM company Senseonics has received approval from the FDA for the non-adjunctive indication for its Eversense device.
Senseonics is only the third company to secure this indication, which allows a CGM to be used for insulin dosing in lieu of a fingerstick glucometer, though patients will still need to use fingersticks twice a day for calibration.
The company plans to go live with the...
March 25, 2019
On Friday, Senseonics, maker of the implantable continuous glucose monitoring system Eversense, announced a new program geared towards patients with high-deductible insurance plans or plans that don’t cover the full cost of the CGM.
The new program, called Eversense Bridge, charges patients $99 for the Eversense CGM system, in addition to the cost of the sensor placement by their provider....
March 14, 2019
Virta Health, the company that controversially claims to reverse Type 2 diabetes using a combination of diet and digitally-powered management efforts, has hired a big name in the digital health space as its new head of commercial: Derek Newell, who served as CEO of Jiff prior to its acquisition by Castlight. Newell stayed on with Castlight as president for a little over a year, according to his...
March 5, 2019
This morning Senseonics, an implantable glucose sensor company, announced that data from its Eversense continuous glucose monitor will be integrated into the Glooko diabetes management platform.
This means that users of the Eversense CGM and app will now be able to sync it with the Glooko online platform and app, and be able to see historical blood glucose-related data as well as get updates...
February 4, 2019
Verily's prototype smart shoe. Verily is shopping for partners to develop a smart shoe with embedded sensors for movement, weight and fall monitoring, according to a CNBC report citing three anonymous sources. The company allegedly has a prototype design of the footwear that it has been showing off in private meetings, and is envisioning the shoe as a health product.
MRIs are A-OK. Senseonics’...
August 9, 2018
Not two months after getting the FDA nod for its implantable CGM, Eversense, Senseonics held its Q2 earnings call reporting a increase in year over year revenues. However, it continues to operate at a net loss.
“In a matter of just six short weeks, we’ve accomplished a lot. We’ve received the authorization from the agency to commercialize in the US, we launched our US commercial activities...
June 25, 2018
This weekend saw the kickoff of the American Diabetes Association’s 78th annual conference, and with it a slew of new data from diabetes management players. The meeting included presentation on studies covering a range of technologies, such as continuous glucose monitors, insulin pumps, apps, and other digital-backed management strategies.
Among the studies highlighted by the association was an...
June 22, 2018
At long last, Eversense, the implantable continuous glucose monitoring system from Senseonics, has received FDA clearance to be marketed in the United States.
“The FDA is committed to advancing novel products that leverage digital technology to improve patient care,” FDA Commissioner Dr. Scott Gottlieb said in a statement. “These technologies allow patients to gain better control over their...
February 21, 2018
Implantable glucose sensor company Senseonics has launched a remote monitoring app for its users in Europe, the Middle East, and Africa, where its CGM system is distributed by Roche.
The app, called Eversense Now, allows users of the sensor to select up to five friends or family members to view their glucose data, which is updated every five minutes. The feature is available for iOS users at the...
November 1, 2017
Implantable continuous glucose monitor (CGM) maker Senseonics is still making the long trudge toward FDA clearance, but at least the company has plenty of European activity to keep it occupied in the meantime.
On a Q3 earnings call, CEO Timothy Goodnow shared details on his company’s continued ramp-ups and rollouts across Europe, its first entry into an international market, and the receipt of a...